Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study

Autor: Cécile Verite-Goulard, Nadir Cheurfa, Laurence Brugières, Sophie Piperno-Neumann, Laure Saumet, Nathalie Gaspar, Nadège Corradini, Perrine Marec-Berard, Hervé Brisse, Marie-Cécile Le Deley, Françoise Rédini, Claudine Schmitt, Gsf-Geto (Groupe Sarcome Français), Jessy Delaye, Hélène Pacquement, Emmanuelle Bompas, Marie-Pierre Castex, Jean-Claude Gentet, Bob-Valéry Occean, Natacha Entz-Werle, Cyril Lervat, Eric Mascard, Marie-Dominique Tabone, Corine Bouvier, Sfce, Antoine Italiano

Publikováno v: European Journal of Cancer
European Journal of Cancer, Elsevier, 2017, 88, pp.57-66. ⟨10.1016/j.ejca.2017.09.036⟩
European Journal of Cancer, 2017, 88, pp.57-66. ⟨10.1016/j.ejca.2017.09.036⟩

Background In most countries, reference chemotherapy for osteosarcoma is MAP regimen (M = high-dose methotrexate, AP = doxorubicin-cisplatinum). In France, the standard preoperative chemotherapy for children/adolescents combines M and etoposide-ifosf

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b208da312db42032cd8ff388934b4d64
https://www.hal.inserm.fr/inserm-01667245